Matt Abernethy - 11 Sep 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Financial Officer
Issuer ticker: NBIX
Reported as of: 11 Sep 2026
Net transaction value: -$363,285
SEC form: 4
Accepted by SEC: 15 Sep 2026, 17:02:22 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Filing notes and source

Key filing fact

Matt Abernethy filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 15 Sep 2026.

Key facts

This page summarizes Matt Abernethy's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Sep 2026, 17:02.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: -$363,285.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724097 Primary reporting owner

ABERNETHY MATT

Relationship: Chief Financial Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 15 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Award

Transaction value
Shares: +5,020
Change %: +12%
Price: $0.000000^*
Shares after: 47,828
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F1

NBIX transaction

Common Stock

Tax liability

Transaction value
Shares: -2,709
Change %: -5.7%
Price: $156.22^*
Shares after: 45,119
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F2

NBIX transaction

Common Stock

Sale

Transaction value: -$363,285
Shares: -2,311
Change %: -5.1%
Price: $157.20
Shares after: 42,808
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

Footnote F2

Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Footnote F3

The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F4

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.